Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sudeep PharmaBOM:544619 +4.41%21 Forward PE Ratio is 48.34 as of Sep. 20, 2026. GuruFocus rates BOM:544619 with a GF Score™ of 21/100. The stock has 8 warning signs investors should review. Among 411 Drug Manufacturers companies, Sudeep Pharma ranks worse than 91.48% on this metric.
Sudeep Pharma's Forward PE Ratio for today is 48.34.
Sudeep Pharma (BOM:544619) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Sudeep Pharma Forward PE Ratio Related Terms
Sudeep Pharma Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Sudeep Pharma's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sudeep Pharma Forward PE Ratio Chart
Sudeep Pharma Annual Data
Trend
2026-03
Forward PE Ratio
35.24
Sudeep Pharma Quarterly Data
2026-03
2026-06
Forward PE Ratio
35.24
49.37
BOM:544619 vs ZTS: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sudeep Pharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sudeep Pharma Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sudeep Pharma's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Sudeep Pharma's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Sudeep Pharma (BOM:544619) has a Forward PE Ratio of 48.34 as of Sep. 20, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Sudeep Pharma and its competitors. According to the industry distribution chart, Sudeep Pharma ranks #376 out of 411 companies in the Drug Manufacturers industry, placing it in the top 91.5%.
Is Sudeep Pharma's Forward PE Ratio too high?
Sudeep Pharma's current Forward PE Ratio is 48.34. The Drug Manufacturers industry median Forward PE Ratio is 15.05. Sudeep Pharma's value of 48.34 is 221.2% above this industry median. Based on the distribution chart, Sudeep Pharma ranks #376 out of 411 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sudeep Pharma has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sudeep Pharma's Forward PE Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Sudeep Pharma ranks #376 out of 411 companies for Forward PE Ratio. This places Sudeep Pharma in the lower half of its industry. The industry median Forward PE Ratio is 15.05. Sudeep Pharma's value of 48.34 is 221.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 15.05, based on 411 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sudeep Pharma's current Forward PE Ratio of 48.34 is 221.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Sudeep Pharma and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 15.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sudeep Pharma's current Forward PE Ratio is 48.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sudeep Pharma stock overvalued right now?
Sudeep Pharma (BOM:544619) has a current Forward PE Ratio of 48.34. The current Forward PE Ratio is 48.34 and 221.2% above the Drug Manufacturers industry median of 15.05. Sudeep Pharma's overall GF Score™ is 21/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Sudeep Pharma (BOM:544619), the current Forward PE Ratio is 48.34 as of Sep. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sudeep Pharma Ltd is a technology led manufacturer of excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries and is dedicated to contributing to the healthcare ecosystem. The company operates in two business verticals: Pharmaceutical, food, and nutrition. It focuses on providing refined, mineral-based single ingredients essential to the pharmaceutical, food, and nutrition industries and Specialty ingredients: It pertains manufacturing of specialty ingredients using advance technology solutions. The maximum revenue is generated from the Pharmaceutical, food, and nutrition segment. Geographically, it has presence in the United States, South America, Europe, the Middle East, Africa, and Asia-Pacific.
21GF Score
Get the complete analysis for BOM:544619
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:544619 has been successfully added to your 
